Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biocorrx Inc (OP:BICX)

0.4498 UNCHANGED
Streaming Delayed Price Updated: 2:53 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biocorrx Inc

< Previous 1 2 3 Next >
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
Via TheNewswire.com
Topics Death
BioCorRx Reports Business Update for the First Quarter of 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
BioCorRx Reports Business Update for the First Quarter of 2025
Via TheNewswire.com
Topics Death
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
ANAHEIM, CA and LOUISVILLE, KY - March 10, 2025 (NEWMEDIAWIRE) - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related... 
Via TheNewswire.com
BioCorRx Reports Business Update for the Second Quarter of 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
BioCorRx Reports Business Update for the First Quarter of 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death Intellectual Property
BioCorRx Reports Business Update for the First Quarter of 2024
ANAHEIM, CA - (NewMediaWire) - May 16, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today... 
Via TheNewswire.com
Topics Death Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
ANAHEIM, CA - (NewMediaWire) - April 03, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of innovative treatment programs for substance use and related disorders, today announced that... 
Via TheNewswire.com
Topics Intellectual Property
BioCorRx Reports Business Update for 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
BioCorRx Reports Business Update for 2023
ANAHEIM, CA - (NewMediaWire) - April 02, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today... 
Via TheNewswire.com
Topics Death
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
ANAHEIM, CA - (NewMediaWire) - February 28, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders,... 
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
ANAHEIM, CA - (NewMediaWire) - February 28, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders,... 
Via TheNewswire.com
Topics Death
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
ANAHEIM, CA - (NewMediaWire) - February 8, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders,... 
Via TheNewswire.com
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Reports Business Update for the Third Quarter of 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Reports Business Update for the Second Quarter of 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
BioCorRx Provides Business Update for the First Quarter of 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Provides Business Update for 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.